90 results on '"Bergamo F"'
Search Results
2. Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience
3. Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study
4. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
5. Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas
6. Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study
7. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies
8. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
9. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
10. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
11. A44 - Partial splenic embolization in chemotherapy-induced thrombocytopenia: a retrospective analysis with long term follow up
12. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer
13. 533P First-line treatment in older patients with metastatic colorectal cancer: A large real-world study.
14. P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer
15. O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO
16. O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)
17. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
18. OC.04.2: EFFECT OF PREOPERATIVE CHEMO-RADIATION ON TUMORINFILTRATING LYMPHOCYTES IN LOCALLY ADVANCED RECTAL CANCER AND TUMOR RESPONSE: RESULTS FROM THE STAR-01 COHORT.
19. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
20. Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings
21. Autonomic neuropathy and transcutaneous oxymetry in diabetic lower extremities
22. The immune microenvironment in pancreatic ductal adenocarcinoma: a potential preoperative marker of lymphnodal involvement.
23. 422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018).
24. 399P Role of geriatric assessment and oncological multidimensional prognostic index in elderly patients with metastatic colorectal cancer in a real-world setting.
25. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
26. 509O Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): First results of NO-CUT trial.
27. Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.
28. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
29. Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer.
30. Physical training prevents body weight gain but does not modify adipose tissue gene expression.
31. Hüftdysplasie und -luxation.
32. The 9p- deletion syndrome A patient with a 45,XX,-9,-15, + t(9/15) constitution due to maternal 3:l meiotic disjunction.
33. 1562P Observational prospective study of Italian guidelines application for patients with pancreatic ductal adenocarcinoma.
34. P-134 - Real-world guideline application in the management of pancreatic cancer patients: the Italian GARIBALDI study.
35. Alterações no líquido sinovial do joelho de cães com osteoartrite induzida pelo modelo Pond e Nuki
36. 1666P Non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-Institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI).
37. 506O Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO.
38. Ethics in the '80s.
39. 498TiP Adjuvant trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: The TRINITY trial
40. 1883P Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial.
41. Application of a sealed tube neutron generator to the characterization of very short half-life isomeric states
42. On a Geometrical Procedure to Construct Approximating Maps for Ordinary Conservative Systems.
43. 182P A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe.
44. 108P Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A translational analysis of the TRIPLETE trial.
45. PD-015 - Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies.
46. 507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer.
47. SO-3 Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: Preliminary results from the multicenter B-REAL study.
48. 185P Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study.
49. 173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB).
50. 154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.